These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1671 related articles for article (PubMed ID: 27401897)

  • 1. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
    Li H; Yao L; Jin P; Hu L; Li X; Guo T; Yang K
    Breast; 2018 Aug; 40():106-115. PubMed ID: 29758503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
    Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
    Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
    Liu Q; Wang C; Li P; Liu J; Huang G; Song S
    Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The accuracy of
    Tian F; Shen G; Deng Y; Diao W; Jia Z
    Eur Radiol; 2017 Nov; 27(11):4786-4796. PubMed ID: 28477166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
    Zhang C; Liang Z; Liu W; Zeng X; Mo Y
    BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis.
    Gu YL; Pan SM; Ren J; Yang ZX; Jiang GQ
    Clin Breast Cancer; 2017 Jul; 17(4):245-255. PubMed ID: 28209330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis.
    Liang X; Yu J; Wen B; Xie J; Cai Q; Yang Q
    Clin Radiol; 2017 Apr; 72(4):295-301. PubMed ID: 28139203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prediction of pathological complete response in luminal B type neoadjuvant chemotherapy-treated breast cancer patients: comparison between interim 18F-FDG PET/CT and MRI.
    Pahk K; Kim S; Choe JG
    Nucl Med Commun; 2015 Sep; 36(9):887-91. PubMed ID: 25932536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.
    Schmitz AMT; Teixeira SC; Pengel KE; Loo CE; Vogel WV; Wesseling J; Rutgers EJT; Valdés Olmos RA; Sonke GS; Rodenhuis S; Vrancken Peeters MJTFD; Gilhuijs KGA
    PLoS One; 2017; 12(5):e0176782. PubMed ID: 28531188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
    Lin CY; Lin CL; Kao CH
    Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
    You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH
    Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer.
    Baysal H; Serdaroglu AY; Ozemir IA; Baysal B; Gungor S; Erol CI; Ozsoy MS; Ekinci O; Alimoglu O
    J Surg Res; 2022 Oct; 278():223-232. PubMed ID: 35636197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of
    Han S; Choi JY
    Breast Cancer Res; 2020 Oct; 22(1):119. PubMed ID: 33129348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.